greeksoup/ stock research

Trulieve Cannabis Corp.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 26 February 2026: press release. The quarter’s numbers.

Key takeaways

  • Full-year revenue flat at $1.2 billion: Full-year revenue was $1,181 million against $1,186 million in 2024, flat year over year. Retail sales were 94% of revenue. Source
  • Full-year adjusted EBITDA reached $427 million: Full-year adjusted EBITDA was $427 million, or 36% of revenue, up $7 million or 2% from 2024. The company described this as a record. Source
  • Branded unit sales rose 5% to 50.1 million: The company sold 50.1 million branded product units in 2025, up 5% from the prior year, which it described as a record. Source
  • Gross margin held at 60%: Full-year gross margin was 60%, with gross profit of $711 million, against $716 million in 2024. Q4 gross margin was 60%, against 62% a year earlier. Source
  • Q4 SG&A fell about 20%: Q4 selling, general and administrative expense was $126.3 million, against $157.9 million a year earlier. Full-year SG&A was $445.2 million, against $510.4 million. Source
  • Operating and free cash flow for the year: Cash flow from operations was $273 million and free cash flow was $229 million for 2025. The company described both as records. Q4 operating cash flow was $59 million. Source
  • 2026 senior notes redeemed in full: The company redeemed $368 million of senior secured notes due 2026 and repaid a $15.8 million mortgage. Private placement notes, net, fell to $136.7 million from $364.8 million. Source
  • Texas conditional license won: The company received conditional approval for a Dispensing Organization license in Texas. Management named it, with the debt repositioning, as a year-end achievement. Source

“We finished the year strong, winning a conditional license in Texas and repositioning our debt,”

Kim Rivers, Trulieve CEO

What changed from last quarter

  • New: Conditional approval for a Dispensing Organization license in Texas, under the Texas Compassionate Use Program. Source
  • New: Closed a $140 million private placement of senior secured notes due 2030, with a second $60 million tranche closed after year end. Source
  • Ended: The $368 million of senior secured notes due 2026 were redeemed, and a $15.8 million mortgage was repaid. The third-quarter release had announced the planned redemption. Source

Results and growth drivers

  • Full-year revenue flat at $1.2 billion: Full-year revenue was $1,181 million against $1,186 million in 2024, flat year over year. Retail sales were 94% of revenue. Source
  • Fourth-quarter revenue down 3% year over year: Q4 revenue was $293 million, down from $301 million in the fourth quarter of 2024 and up from $288 million in the third quarter. Retail sales were 93% of Q4 revenue. Source
  • Full-year adjusted EBITDA reached $427 million: Full-year adjusted EBITDA was $427 million, or 36% of revenue, up $7 million or 2% from 2024. The company described this as a record. Source
  • Full-year net loss narrowed: Net loss attributable to common shareholders was $116 million for 2025, against $155 million in 2024. Adjusted net loss was $27 million, against $19 million. Source
  • Fourth-quarter net loss narrowed: Q4 net loss attributable to common shareholders was $43 million, against $60 million a year earlier. EPS from continuing operations was $(0.23), against $(0.26). Source

Retail footprint and regions

  • Dispensary count rose to 234: The company added 11 dispensaries in 2025, ending the year at 233 locations. It opened one in Findlay, Ohio in Q4 and one in Fort Myers, Florida after year end. The third-quarter release reported 232. Source
  • Core markets are Arizona, Florida, Pennsylvania: The company describes its leading market positions as being in Arizona, Florida and Pennsylvania. Source

“With rescheduling on the horizon, Trulieve is carrying the momentum into 2026, prioritizing expanded access, loyal customers, branded products and growth initiatives.”

Kim Rivers, Trulieve CEO

Products and customers

  • Branded unit sales rose 5% to 50.1 million: The company sold 50.1 million branded product units in 2025, up 5% from the prior year, which it described as a record. Source
  • Rewards membership reached 915,000: Rewards program membership was 915,000 at December 31, 2025. The third-quarter release reported 820,000 members at September 30, 2025. Source
  • Florida mobile app lets patients reserve products: The app lets Florida patients browse and reserve products, view promotions and check rewards status. The third-quarter release also listed its launch. Source

Costs, margins and pricing

  • Gross margin held at 60%: Full-year gross margin was 60%, with gross profit of $711 million, against $716 million in 2024. Q4 gross margin was 60%, against 62% a year earlier. Source
  • Q4 SG&A fell about 20%: Q4 selling, general and administrative expense was $126.3 million, against $157.9 million a year earlier. Full-year SG&A was $445.2 million, against $510.4 million. Source
  • Political contributions lower than 2024: Campaign and political contributions were $66.1 million for 2025, against $117.5 million in 2024. Q4 contributions were $32.4 million, against $54.8 million. Source

Cash flow, debt and capital

  • Operating and free cash flow for the year: Cash flow from operations was $273 million and free cash flow was $229 million for 2025. The company described both as records. Q4 operating cash flow was $59 million. Source
  • 2026 senior notes redeemed in full: The company redeemed $368 million of senior secured notes due 2026 and repaid a $15.8 million mortgage. Private placement notes, net, fell to $136.7 million from $364.8 million. Source
  • Second $60 million notes tranche closed: After year end the company closed a second tranche of $60 million in private placement senior secured notes due 2030, following the $140 million placement. Source
  • Year-end cash of $256 million: Cash and cash equivalents were $255.5 million at December 31, 2025, against $238.8 million a year earlier, with no short-term investments held at year end. Source
  • Uncertain tax position liabilities increased: Uncertain tax position liabilities on the balance sheet were $668.4 million, up from $445.2 million. Operating cash flow included $223.2 million for this item in 2025. Source

Strategy, licensing and investment

  • Texas conditional license won: The company received conditional approval for a Dispensing Organization license in Texas. Management named it, with the debt repositioning, as a year-end achievement. Source
  • Capital spending down sharply: Purchases of property and equipment were $44.2 million for 2025, against $122.6 million in 2024. Q4 purchases were $3.4 million, against $42.7 million. Internal use software purchases were $16.3 million. Source
  • Hub strategy for retail and distribution: The company describes its strategy as building scale in retail and distribution in new and existing markets through a hub strategy. Source

Leadership and reform progress

  • Reform progress cited last quarter: The third-quarter release said the 2025 strategic plan showed demonstrable progress on reform, customers, distribution and branded products.
  • CFO added and board seat filled: The third-quarter release reported that Jan Reese was added as Chief Financial Officer and Matthew Foulston was appointed to the Board of Directors.

Coming up, as management said on 26 February 2026

  • 2025 Form 10-K to be filed: The Form 10-K for 2025 will be available on the SEC website and on the company's quarterly results page. Source

Earlier plans management reported on

  • Met: Announced as planned in the third-quarter release. The fourth-quarter release reports the redemption completed, along with repayment of a $15.8 million mortgage. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.